Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Nintedanib (formerly known as BIBF 1120) is an intracellular inhibitor that targets multiple tyrosine kinases. A phase 2 trial suggested that treatment with 150 mg of nintedanib twice daily reduced lung-function decline and acute exacerbations in patients with idiopathic pulmonary fibrosis. METHODS: We conducted two replicate 52-week, randomized, double-blind, phase 3 trials (INPULSIS-1 and INPULSIS-2) to evaluate the efficacy and safety of 150 mg of nintedanib twice daily as compared with placebo in patients with idiopathic pulmonary fibrosis. The primary end point was the annual rate of decline in forced vital capacity (FVC). Key secondary end points were the time to the first acute exacerbation and the change from baseline in the total score on the St. George's Respiratory Questionnaire, both assessed over a 52-week period. RESULTS: A total of 1066 patients were randomly assigned in a 3:2 ratio to receive nintedanib or placebo. The adjusted annual rate of change in FVC was -114.7 ml with nintedanib versus -239.9 ml with placebo (difference, 125.3 ml; 95% confidence interval [CI], 77.7 to 172.8; P<0.001) in INPULSIS-1 and -113.6 ml with nintedanib versus -207.3 ml with placebo (difference, 93.7 ml; 95% CI, 44.8 to 142.7; P<0.001) in INPULSIS-2. In INPULSIS-1, there was no significant difference between the nintedanib and placebo groups in the time to the first acute exacerbation (hazard ratio with nintedanib, 1.15; 95% CI, 0.54 to 2.42; P=0.67); in INPULSIS-2, there was a significant benefit with nintedanib versus placebo (hazard ratio, 0.38; 95% CI, 0.19 to 0.77; P=0.005). The most frequent adverse event in the nintedanib groups was diarrhea, with rates of 61.5% and 18.6% in the nintedanib and placebo groups, respectively, in INPULSIS-1 and 63.2% and 18.3% in the two groups, respectively, in INPULSIS-2. CONCLUSIONS: In patients with idiopathic pulmonary fibrosis, nintedanib reduced the decline in FVC, which is consistent with a slowing of disease progression; nintedanib was frequently associated with diarrhea, which led to discontinuation of the study medication in less than 5% of patients. (Funded by Boehringer Ingelheim; INPULSIS-1 and INPULSIS-2 ClinicalTrials.gov numbers, NCT01335464 and NCT01335477.).
Overview
CoChat Summary
TL;DR
This paper reports two replicate 52-week phase 3 randomized trials showing that nintedanib slowed the decline in forced vital capacity in idiopathic pulmonary fibrosis. Diarrhea was common, but discontinuation due to study medication occurred in less than 5% of patients.
Key findings
- In INPULSIS-1, the adjusted annual rate of change in FVC was -114.7 ml with nintedanib vs -239.9 ml with placebo; the between-group difference was 125.3 ml (95% CI, 77.7 to 172.8; P<0.001).
- In INPULSIS-2, the adjusted annual rate of change in FVC was -113.6 ml with nintedanib vs -207.3 ml with placebo; the between-group difference was 93.7 ml (95% CI, 44.8 to 142.7; P<0.001).
- For time to first acute exacerbation, INPULSIS-1 showed no significant difference (HR 1.15, 95% CI, 0.54 to 2.42; P = 0.67), while INPULSIS-2 showed benefit with nintedanib (HR 0.38, 95% CI, 0.19 to 0.77; P = 0.005).
- The most frequent adverse event was diarrhea: 61.5% vs 18.6% in INPULSIS-1 and 63.2% vs 18.3% in INPULSIS-2 for nintedanib vs placebo, respectively; the conclusion states this led to discontinuation in less than 5% of patients.
Methods
- Two replicate 52-week, randomized, double-blind, phase 3 trials (INPULSIS-1 and INPULSIS-2) compared nintedanib 150 mg twice daily with placebo in patients with idiopathic pulmonary fibrosis.
- 1066 patients were randomly assigned in a 3:2 ratio to nintedanib or placebo.
- Primary outcome was the annual rate of decline in forced vital capacity (FVC); key secondary outcomes were time to first acute exacerbation and change in St. George’s Respiratory Questionnaire total score over 52 weeks.
Limitations
- The text does not state formal study limitations.
- Evident from the paper’s own reporting: the effect on acute exacerbation was inconsistent across the two replicate trials (no significant difference in INPULSIS-1, significant benefit in INPULSIS-2).
- Evident from the text: the provided excerpt does not report the full results for the St. George’s Respiratory Questionnaire outcome, so that secondary endpoint cannot be fully summarized from this text alone.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
0 Valid · 1 Not valid · 0 Not checked · 11 Own results and interpretations
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“which led to discontinuation of the study medication in less than 5% of patients.”
states a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: unclear — It is unclear why the paper says it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“in INPULSIS-2, there was a significant benefit with nintedanib versus placebo (hazard ratio, 0.38; 95% CI, 0.19 to 0.77; P = 0.005).”
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“and -113.6 ml with nintedanib versus -207.3 ml with placebo (difference, 93.7 ml; 95% CI, 44.8 to 142.7; P<0.001) in INPULSIS-2.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“and 63.2% and 18.3% in the two groups, respectively, in INPULSIS-2.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The adjusted annual rate of change in FVC was -114.7 ml with nintedanib versus -239.9 ml with placebo (difference, 125.3 ml; 95% confidence interval [CI], 77.7 to 172.8; P<0.001) in INPULSIS-1”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
5 more claims
Create a free account to see all 12 claims and every source verdict.
- It may state two separate claims as one. 1
- Probably not a substantial claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Idiopathic pulmonary fibrosis (IPF), the prototype of fibrotic ILDs, carries a prognosis of 3–5 years survival after diagnosis when untreated. Two anti-fibrotic medications (nintedanib and pirfenidone) have been shown to reduce the rate of forced vital capacity (FVC) decline and slow disease progression in patients with a definite usual interstitial pneumonia (UIP) pattern and with a probable UIP pattern on high resolution CT (HRCT).(191–193)”
From Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. (2021) · cites this paper as [192]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, both have significant adverse effects and neither completely arrest the decline in lung function.”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Reported adverse events in the present trial were generally acceptable and largely consistent with events previously reported by participants in the placebo arms of randomized controlled trials in IPF [45,46].”
From Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study (2019) · cites this paper as [46]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“nintedanib, which was originally developed with oncology in mind, for treatment of idiopathic pulmonary fibrosis150.”
From A framework for advancing our understanding of cancer-associated fibroblasts (2020) · cites this paper as [150]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Clinical trials investigating these two drugs in patients with IPF have demonstrated only a slowing of disease progression33,34, as measured by forced vital capacity (FVC) and self-reported quality of life (QOL) metrics, and unclear benefit to survival26, making the development of therapies that can restore lung function and reverse the course of disease a priority.”
From A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial (2025) · cites this paper as [34]
Experimental — accuracy not yet measured
8 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Miller, M. R., Hankinson, J., Brusasco, V., Burgos, F., Casaburi, R., Coates, A., Crapo, R., Enright, P., van der Grinten, C. P. M., Gustafsson, P., et al. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00034805 · Cited by 15,627
Raghu, G., Collard, H. R., Egan, J. J., Martinez, F. J., Behr, J., Brown, K. K., Colby, T. V., Cordier, J.-F., Flaherty, K. R., Lasky, J. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2009-040gl · Cited by 7,186
Self-citationThe St George's Respiratory Questionnaire
Jones, P. W., Quirk, F. H., & Baveystock, C. M. (1991) · Respiratory Medicine · doi:10.1016/s0954-6111(06)80166-6 · Cited by 2,683
King, T. E., Pardo, A., & Selman, M. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60052-4 · Cited by 2,194
Self-citationEfficacy of a Tyrosine Kinase Inhibitor in Idiopathic Pulmonary Fibrosis
Richeldi, L., Costabel, U., Selman, M., Kim, D. S., Hansell, D. M., Nicholson, A. G., Brown, K. K., Flaherty, K. R., Noble, P. W., Raghu, G., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103690 · Cited by 1,157
Self-citationAcute Exacerbations of Idiopathic Pulmonary Fibrosis
Collard, H. R., Moore, B. B., Flaherty, K. R., Brown, K. K., Kaner, R. J., King, T. E., Lasky, J. A., Loyd, J. E., Noth, I., Olman, M. A., et al. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200703-463pp · Cited by 1,130
Self-citationBIBF 1120: Triple Angiokinase Inhibitor with Sustained Receptor Blockade and Good Antitumor Efficacy
Hilberg, F., Roth, G. J., Krssak, M., Kautschitsch, S., Sommergruber, W., Tontsch-Grunt, U., Garin-Chesa, P., Bader, G., Zoephel, A., Quant, J., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6307 · Cited by 1,056
St. George's Respiratory Questionnaire: MCID
Jones, P. W. (2005) · COPD: Journal of Chronic Obstructive Pulmonary Disease · doi:10.1081/copd-200050513 · Cited by 855
Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome
Song, J. W., Hong, S.-B., Lim, C.-M., Koh, Y., & Kim, D. S. (2011) · European Respiratory Journal · doi:10.1183/09031936.00159709 · Cited by 783
Self-citationChanges in Clinical and Physiologic Variables Predict Survival in Idiopathic Pulmonary Fibrosis
Collard, H. R., King, T. E., Bartelson, B. B., Vourlekis, J. S., Schwarz, M. I., & Brown, K. K. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200211-1311oc · Cited by 764
Self-citation
Cited by
Items 2,701–2,800 of 4,628
Inoue, Y., Kitamura, H., Okamoto, M., Ogura, T., Nishioka, Y., Kuwana, M., Taniguchi, A., Ito, T., Rohr, K. B., & Suda, T. (2024) · Respiratory Investigation · doi:10.1016/j.resinv.2024.04.008 · Cited by 7
Self-citationWhen the Third Time Is Not the Charm—Trial Outcomes in Idiopathic Pulmonary Fibrosis
Zamora, A., Ortega, V. E., & Carmona, E. M. (2024) · JAMA · doi:10.1001/jama.2024.8776 · Cited by 7
Song, D., Tang, X., Du, J., et al. (2024) · PLoS ONE · doi:10.1371/journal.pone.0305409 · Cited by 6
Adiponectin suppresses stiffness-dependent, profibrotic activation of lung fibroblasts
Németh, J., Skrońska-Wąsek, W., Keppler, S., Schundner, A., Groß, A., Schönberger, T., Quast, K., Kasmi, K. C. E., Ruppert, C., Guenther, A., et al. (2024) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00037.2024 · Cited by 9
Effects of nintedanib on circulating biomarkers of idiopathic pulmonary fibrosis
Jenkins, R. G., Cottin, V., Nishioka, Y., Noth, I., White, E. S., Ittrich, C., Diefenbach, C., Rohr, K. B., Selman, M., & Maher, T. M. (2024) · ERJ Open Research · doi:10.1183/23120541.00558-2023 · Cited by 6
Self-citationThe Impact of Nintedanib Dosing on Clinical Outcomes
LIMPER, A. H., Thao, V., Helfinstine, D. A., Sangaralingham, L. R., & Dempsey, T. M. (2024) · CHEST Journal · doi:10.1016/j.chest.2024.09.030 · Cited by 7
Mohamed, R., Sangani, R. G., Kamal, K. M., LeMaster, T. J., Rudisill, T. M., Scott, V., Kelley, G. A., & Wen, S. (2024) · Medicine Advances · doi:10.1002/med4.86 · Cited by 7
Yang, M., Tan, Y., Yang, T., Xu, D., Chen, M., & Chen, L. (2025) · PLoS ONE · doi:10.1371/journal.pone.0318877 · Cited by 9
Quan, J., Ma, C., Zhao, X., Guo, Y., Qu, W., Zhou, X., Ma, E., & Xu, Y. (2025) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2025.108360 · Cited by 6
Bayrak, E., Bayır, E., Baysoy, E., Özcan, A., Ayan, B., Saygılı, E., & Kaleli‐Can, G. (2025) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2025.114652 · Cited by 9
Ikeda, S., Sekine, A., Baba, T., Yamakawa, H., Morita, M., Kitamura, H., & Ogura, T. (2016) · BMC Pulmonary Medicine · doi:10.1186/s12890-016-0201-9 · Cited by 6
Computational insights into the binding of IN17 inhibitors to MELK
Harger, M., Lee, J., Walker, B., Taliaferro, J. M., Edupuganti, R., Dalby, K. N., & Ren, P. Y. (2019) · Journal of Molecular Modeling · doi:10.1007/s00894-019-4036-1 · Cited by 6
Sadon, A. A.-A., Kenawy, A. S., Abdelsalam, A., & Attia, H. (2020) · Egyptian Journal of Chest Diseases and Tuberculosis · doi:10.4103/ejcdt.ejcdt_140_19 · Cited by 6
Early diagnosis of idiopathic pulmonary fibrosis: Closer to the goal?
Comes, A., Sgalla, G., & Richeldi, L. (2020) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2020.08.018 · Cited by 5
Self-citationZheng, X.-F., Xie, B., Liu, Y., Zhu, M., Zhang, S., Ban, C., Geng, J., Jiang, D., Ren, Y., Dai, H., et al. (2020) · Chinese Medical Journal · doi:10.1097/cm9.0000000000001089 · Cited by 6
Is operation safe for lung cancer patients with interstitial lung disease on computed tomography?
Tang, H., Ren, Y., She, Y., Dai, C., Wang, T., Su, H., Sun, W., Jiang, G., & Chen, C. (2020) · Therapeutic Advances in Respiratory Disease · doi:10.1177/1753466620971137 · Cited by 7
Dorey-Stein, Z. L., Shapiro, W., Zhao, H., CORDOVA, F. C., Criner, G. J., & Galli, J. A. (2021) · Respiratory Medicine · doi:10.1016/j.rmed.2021.106599 · Cited by 7
Samhouri, B. F., Kanj, A., Chehab, O., & Ryu, J. H. (2022) · Mayo Clinic Proceedings Innovations Quality & Outcomes · doi:10.1016/j.mayocpiqo.2021.12.003 · Cited by 7
Coronary artery calcium score is a prognostic factor for mortality in idiopathic pulmonary fibrosis
Caminati, A., Zompatori, M., Fuccillo, N. R. T. D. A., Sonaglioni, A., Elia, D., Cassandro, R., Trevisan, R., Rispoli, A., Pelosi, G., & Harari, S. A. (2022) · Minerva Medica · doi:10.23736/s0026-4806.22.08018-1 · Cited by 8
Im, C., Yan Yuan, A., Austin, E. D., Stokes, D. C., Krasin, M. J., Davidoff, A. M., Sapkota, Y., Wang, Z., Ness, K. K., Wilson, C. L., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-22-0418 · Cited by 9
Ogura, T., Suda, T., Inase, N., Nishioka, Y., Azuma, A., Okamoto, M., Takizawa, A., Ito, T., Rohr, K. B., & Inoue, Y. (2022) · Respiratory Investigation · doi:10.1016/j.resinv.2022.06.009 · Cited by 6
Self-citationArai, T., & Inoue, Y. (2022) · ERJ Open Research · doi:10.1183/23120541.00242-2022 · Cited by 8
Self-citationWang, F., Zhang, Y., Ren, J. F., & Yu, W. (2022) · Folia Histochemica et Cytobiologica · doi:10.5603/fhc.a2022.0022 · Cited by 7
Design and rationale of the Japanese Idiopathic Interstitial Pneumonias (JIPS) Registry
Okuda, R., Ogura, T., Hisata, S., Baba, T., Kondoh, Y., Suda, T., Johkoh, T., Iwasawa, T., Tomioka, H., Bando, M., et al. (2022) · Respiratory Investigation · doi:10.1016/j.resinv.2022.08.009 · Cited by 7
Self-citationLi, H., Yang, J., Chen, S., Wang, P., Yu, X., Zhou, Q., Zhang, X., & Zhang, G. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1055702 · Cited by 9
“The Ascend study (Richeldi et al., 2014) found that the annual FVC decline was 428 ml in the placebo group versus 235 ml in the pirfenidone group.”
BackgroundYagasaki, H., Takekoshi, S., Kitatani, K., Kato, C., Yamasaki, H., Shioyama, K., Tsuboi, T., Matsuzaki, T., Inagaki, Y., Masuda, R., et al. (2022) · Free Radical Research · doi:10.1080/10715762.2022.2092477 · Cited by 7
Chikina, S. Y., Cherniak, A. V., Мержоева, З. М., Tyurin, I. E., Трушенко, Н. В., Proshkina, A. A., Ataman, K. S., & Avdeev, S. N. (2023) · Life · doi:10.3390/life13020435 · Cited by 7
Machine Learning and BMI Improve the Prognostic Value of GAP Index in Treated IPF Patients
Lacedonia, D., Pace, C. C. D., Rea, G., Capitelli, L., Gallo, C., Scioscia, G., Tondo, P., & Bocchino, M. (2023) · Bioengineering · doi:10.3390/bioengineering10020251 · Cited by 7
“After four years, nintedanib was approved [6,7], the second and, currently, the last pharmacological treatment.”
BackgroundTopological data analysis identifies molecular phenotypes of idiopathic pulmonary fibrosis
Shapanis, A. G., Jones, M. G., Schofield, J. P. R., & Skipp, P. J. S. (2023) · Thorax · doi:10.1136/thorax-2022-219731 · Cited by 7
Karampitsakos, Τ., Galaris, A., Barbayianni, I., DeIuliis, G., Ahangari, F., Sampsonas, F., Sotiropoulou, V., Aidinis, V., Bennett, A. M., Herazo‐Maya, J. D., et al. (2023) · Diagnostics · doi:10.3390/diagnostics13061166 · Cited by 6
Anti-fibrotic strategies and pulmonary fibrosis
Gunatilaka, A., Zhang, S., Tan, W. S. D., & Stewart, A. G. (2023) · Advances in pharmacology · doi:10.1016/bs.apha.2023.04.002 · Cited by 7
Research and development of N , N ′-diarylureas as anti-tumor agents
Sun, X., Xie, Z., Lei, X., Sheng, H., Tang, G., & Wang, Z. (2023) · RSC Medicinal Chemistry · doi:10.1039/d3md00053b · Cited by 6
Bahri, S., Omrani, R., Jebli, N., Nahdi, A., Mlika, M., Ouederni, A. R. E., Jameleddine, S. B. K., & Ali, R. B. (2023) · Russian Journal of Bioorganic Chemistry · doi:10.1134/s1068162023040064 · Cited by 6
Prostaglandin E2 (PGE2) and Roflumilast Involvement in IPF Progression
Moshkovitz, N., Shochet, G. E., & Shitrit, D. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241512393 · Cited by 8
Jastrzębski, D., Kostorz‐Nosal, S., Galle, D., et al. (2023) · Health Science Reports · doi:10.1002/hsr2.1449 · Cited by 6
Gao, Y., Yang, Z., He, K., Wang, Z., Zhang, T., Jiang, Y., & Zhao, L. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.122066 · Cited by 6
Bräunlich, J., Köhler, M., & Wirtz, H. R. W. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12185853 · Cited by 7
“For several years now, there have been drugs available with considerable effects on the fibrosing process [1,2].”
BackgroundNintedanib-induced osteomyelitis of the jaw against the background of COVID-19 infection
Kudva, A., Saha, M., Gadicherla, S., Arun, S., & Sharma, S. (2023) · Journal of Stomatology Oral and Maxillofacial Surgery · doi:10.1016/j.jormas.2023.101651 · Cited by 6
Moncomble, E., Weisenburger, G., Picard, C., Dégot, T., Reynaud‐Gaubert, M., Nieves, A., Mornex, J., Dauriat, G., Messika, J., Godet, C., et al. (2023) · Respirology · doi:10.1111/resp.14605 · Cited by 7
Diagnostic Approaches for Idiopathic Pulmonary Fibrosis
Lee, J. H., & Song, J. W. (2023) · Tuberculosis & respiratory diseases · doi:10.4046/trd.2023.0087 · Cited by 10
Development of a Novel Biomarker for the Progression of Idiopathic Pulmonary Fibrosis
Yeo, H. J., Ha, M., Shin, D. H., Lee, H. R., Kim, Y. H., & Cho, W. H. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25010599 · Cited by 9
A formula for predicting emphysema extent in combined idiopathic pulmonary fibrosis and emphysema
Wells, A. U., Jacob, J., Sverzellati, N., Cross, G., Barnett, J. L., Lauretis, A. D., Antoniou, K. M., Weycker, D. A., Atwood, M., Kirchgaessler, K.-U., et al. (2024) · Respiratory Research · doi:10.1186/s12931-023-02589-x · Cited by 6
Self-citationBrg1/PRMT5 nuclear complex epigenetically regulates FOXO1 in IPF mesenchymal progenitor cells
Jbeli, A. H., Yang, L., Hong, X., et al. (2024) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00248.2023 · Cited by 6
Auberle, C., Gao, F., Sloan, J. M., Morgensztern, D., Winkler, L., Ward, J. P., Devarakonda, S. H. K., Rearden, T. P., Govindan, R., & Waqar, S. N. (2024) · Journal of Thoracic Disease · doi:10.21037/jtd-23-1717 · Cited by 6
Lee, K. S., Yeom, S. H., Kim, M. K., Woo, C. H., Choi, Y. C., Choi, J. S., & Cho, Y. W. (2024) · Extracellular Vesicle · doi:10.1016/j.vesic.2024.100045 · Cited by 7
Mathai, S. K., & Schwartz, D. A. (2015) · European Respiratory Journal · doi:10.1183/09031936.00052715 · Cited by 7
Idiopathic pulmonary fibrosis: moving forward
Richeldi, L. (2015) · BMC Medicine · doi:10.1186/s12916-015-0481-6 · Cited by 6
Self-citationKristof, A. S., Petrof, B. J., Hamid, Q. A., Kolb, M. R. J., Landry, J., MacKenzie, A., McCormack, F. X., Murawski, I. J., Moss, J., Rauch, F., et al. (2017) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201705-406ws · Cited by 7
Self-citationDavis, S., Rafia, R., Carroll, C., Hamilton, J., & Essat, M. (2018) · PharmacoEconomics · doi:10.1007/s40273-018-0727-1 · Cited by 6
Another Weapon in the Battle against Idiopathic Pulmonary Fibrosis?
Wilson, C. L., & Hung, C. F. (2019) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2018-0387ed · Cited by 6
Bullous pemphigoid associated with nintedanib
Hasson, A. M., Cheeney, G., Ho, L. A., & Vary, J. C. (2019) · JAAD Case Reports · doi:10.1016/j.jdcr.2019.07.028 · Cited by 6
“The most common adverse effects from nintedanib are gastrointestinal events, mainly diarrhea.(3,4) Reports of adverse dermatologic effects from nintedanib are less common, and there are no reports, to our knowledge, of nintedanib-induced BP.”
BackgroundPluchart, H., Chanoine, S., Briault, A., Claustre, J., & Bedouch, P. (2019) · Fundamental and Clinical Pharmacology · doi:10.1111/fcp.12522 · Cited by 7
Parametric Time‐to‐Event Model for Acute Exacerbations in Idiopathic Pulmonary Fibrosis
Tang, F., Weber, B., Stowasser, S., & Korell, J. (2020) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12485 · Cited by 6
“The fact that the observed data from INPULSIS supported a constant hazard model was consistent with the clinical observation that acute exacerbation could occur at any point of time in the course of disease.(4)”
ResultSelf-citationHigo, H., Miyahara, N., Taniguchi, A., Senoo, S., Itano, J., Watanabe, H., Oda, N., Kayatani, H., Ichikawa, H., Shibayama, T., et al. (2020) · Respiratory Investigation · doi:10.1016/j.resinv.2019.12.007 · Cited by 9
Sokai, A., Handa, T., Oga, T., Tanizawa, K., Ikezoe, K., Nakatsuka, Y., Kubo, T., Kumiko, K., Chin, K., & Mishima, M. (2017) · Sarcoidosis vasculitis and diffuse lung diseases · doi:10.36141/svdld.v34i3.5214 · Cited by 9
Clinical course and prognosis in survivors of acute exacerbations of idiopathic pulmonary fibrosis
Yamazaki, R., Nishiyama, O., Yoshikawa, K., Saeki, S., Sano, H., Iwanaga, T., & Tohda, Y. (2021) · Respiratory Investigation · doi:10.1016/j.resinv.2020.12.006 · Cited by 6
Wells, A. U., & Kouranos, V. (2021) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2021.1968832 · Cited by 6
Vonk, M. C., del Castillo, A. G., Kreuter, M., Avis, M., Marzin, K., Mack, S. R., Wind, S., & Gahlemann, M. (2021) · European Journal of Drug Metabolism and Pharmacokinetics · doi:10.1007/s13318-021-00728-7 · Cited by 7
Antifibrotic Therapy for Idiopathic Pulmonary Fibrosis
Khor, Y. H. (2021) · CHEST Journal · doi:10.1016/j.chest.2021.07.033 · Cited by 7
Klay, D., van der Vis, J. J., Roothaan, S. M., Nguyen, T. Q., Grutters, J. C., Goldschmeding, R., & van Moorsel, C. H. M. (2021) · Lung · doi:10.1007/s00408-021-00494-y · Cited by 7
Wang, J., Zhao, X., Feng, W., Li, Y., & Peng, C. Y. (2021) · The American Journal of Chinese Medicine · doi:10.1142/s0192415x21500932 · Cited by 6
Nintedanib in the management of pulmonary fibrosis after COVID-19: a case report
Chakrabortty, R., Rahman, S., Jahan, R., Dip, A. H., & Rahman, M. M. (2021) · BIRDEM Medical Journal · doi:10.3329/birdem.v11i2.53139 · Cited by 6
Nintedanib reduces alloimmune-induced chronic airway changes in murine tracheal allografts
Mauer, J., Kuckhahn, A. V., Ramsperger-Gleixner, M., Ensminger, S. M., Distler, J. H. W., Weyand, M., & Heim, C. (2022) · Transplant Immunology · doi:10.1016/j.trim.2022.101608 · Cited by 7
Schnitzler, M. A., Valapour, M., Skeans, M. A., et al. (2016) · American Journal of Transplantation · doi:10.1111/ajt.13672 · Cited by 6
Immunity, Ciliated Epithelium, and Mortality
Juan-Guardela, B. M., & Herazo‐Maya, J. D. (2022) · CHEST Journal · doi:10.1016/j.chest.2022.02.018 · Cited by 6
Wang, Y., Gong, X., Hu, Y., Yi, Q., Zhang, Q., Miao, L., & Zhou, Y. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.873709 · Cited by 7
“6% under natural progression (8), while chemotherapy-related AEILD mostly occurs within 4 months.”
BackgroundFikry, H., Saleh, L. A., & Gawad, S. A. (2022) · PubMed · doi:10.14670/hh-18-493 · Cited by 8
Xiong, H., Tan, Q., Luo, F., et al. (2022) · International Journal of Rheumatic Diseases · doi:10.1111/1756-185x.14430 · Cited by 6
Pulmonary Hypertension in Scleroderma– Evaluation and Management
Chennakesavulu, P. V., Uppaluri, S., Koyi, J., Jhaveri, S., Avanthika, C., Sakhamuri, L. T., Ashokbhai, P. K., & Singh, P. (2022) · Disease-a-Month · doi:10.1016/j.disamonth.2022.101468 · Cited by 7
Content Analysis of Idiopathic Pulmonary Fibrosis-Related Information on Twitter
Ong, S., Koo, J., Johannson, K. A., Ryerson, C. J., & Goobie, G. C. (2022) · ATS Scholar · doi:10.34197/ats-scholar.2022-0054oc · Cited by 6
The Syndrome of Combined Pulmonary Fibrosis and Emphysema
Cottin, V. (2023) · Springer eBooks · doi:10.1007/978-3-031-12950-6_33 · Cited by 6
Self-citationDsouza, K. G., Alexander, A. S., Watts, J. R., & Kulkarni, T. (2023) · Multidisciplinary Respiratory Medicine · doi:10.4081/mrm.2023.890 · Cited by 12
Kass, D. J., Flynn, M., & Baker, E. (2015) · Current Biomarker Findings · doi:10.2147/cbf.s81362 · Cited by 7
Diagnosing idiopathic pulmonary fibrosis without a lung biopsy: honeycombing not required
Homer, R., & Lederer, D. J. (2017) · Thorax · doi:10.1136/thoraxjnl-2016-209831 · Cited by 6
Interstitial Lung Disease, Body Mass Index, Energy Expenditure and Malnutrition—a Review
Rinaldi, S., Mura, M., & Madill, J. (2017) · Current Pulmonology Reports · doi:10.1007/s13665-017-0168-x · Cited by 7
Pneumatosis Intestinalis Associated with the Tyrosine Kinase Inhibitor Nintedanib
Poor, A. D., & Braman, S. S. (2018) · Lung · doi:10.1007/s00408-018-0118-6 · Cited by 6
Key, A. L., Holt, K. J., Warburton, C. J., Walker, P. P., & Earis, J. E. (2018) · Postgraduate Medical Journal · doi:10.1136/postgradmedj-2017-135320 · Cited by 7
P311 in Scar Wars: Myofibroblasts Lost without Transforming Growth Factor β Translation
Lagares, D. (2018) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2018-0255ed · Cited by 6
Pozo, K., Zahler, S., Ishimatsu, K., Carter, A. M., Telange, R., Tan, C., Wang, S., Pfragner, R., Fujimoto, J., Grubbs, E. G., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.26480 · Cited by 7
Use of nintedanib in patients with idiopathic pulmonary fibrosis: Initial Indian experience
Mullerpattan, J., Porwal, S., Sarkar, T., Wagh, H., & Udwadia, Z. (2019) · Lung India · doi:10.4103/lungindia.lungindia_195_19 · Cited by 6
Three Steps to Cure Pulmonary Fibrosis. Step 1: The Runaway Train or Groundhog Day?
Jenkins, G. R. (2020) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202002-0260ed · Cited by 6
Disease progression across the spectrum of idiopathic pulmonary fibrosis: A multicentre study
Sgalla, G., Greco, E. L., Calvello, M., Varone, F., Iovene, B., Cerri, S., Donatelli, P., Vancheri, A., Pavone, M., Luppi, F., et al. (2020) · Respirology · doi:10.1111/resp.13805 · Cited by 7
Self-citationOpportunities to diagnose fibrotic lung diseases in routine care: A primary care cohort study
Jones, M. G., Hillyar, C., Nibber, A., Chisholm, A., Wilson, A. M., Maher, T. M., Kaplan, A. G., Price, D. B., Walsh, S. L. F., Richeldi, L., et al. (2020) · Respirology · doi:10.1111/resp.13836 · Cited by 6
“Anthropomorphic and lung function measures are consistent with previous IPF cohorts [6,8,9,21].”
BackgroundResultSelf-citationMiyahara, S., Waseda, R., Tokuishi, K., Satō, T., Iwasaki, A., & Shiraishi, T. (2021) · Respiratory Investigation · doi:10.1016/j.resinv.2021.03.006 · Cited by 6
Okusaka, T., Otsuka, T., Ueno, H., Mitsunaga, S., Sugimoto, R., Muro, K., Saito, I., Tadayasu, Y., Inoue, K., Loembé, A., et al. (2016) · Cancer Science · doi:10.1111/cas.13077 · Cited by 5
Update in Interstitial Lung Disease 2016
Wells, A. U., & Maher, T. M. (2017) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201702-0351up · Cited by 8
Broad Adoption of Antifibrotics in Idiopathic Pulmonary Fibrosis: Still a Long Way to Go
Assayag, D. (2021) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202102-123ed · Cited by 6
Dubey, S., & Woodhead, F. (2023) · Rheumatology International · doi:10.1007/s00296-023-05505-0 · Cited by 6
Nanodrug delivery system for precision treatment of pulmonary fibrosis
Yi, X., Zhang, X., Guan, Y., Sha, Y., Cheng, X., Lee, Y. C., & Yuan, W. (2025) · Precision medicine and engineering. · doi:10.1016/j.preme.2025.100025 · Cited by 8
Kim, G. H. J., Zhang, X., Brown, M. S., Poole, L., & Goldin, J. G. (2025) · BMJ Open · doi:10.1136/bmjopen-2024-094559 · Cited by 8
Castelli, G., Cocconcelli, E., Grimaudo, G., Leo, I. D., Bellani, S., Fiorentù, G., Giulianelli, G., Bernardinello, N., Balestro, E., & Spagnolo, P. (2025) · Journal of Personalized Medicine · doi:10.3390/jpm15050213 · Cited by 7
“Moreover, there is also evidence on the beneficial effect of nintedanib on the outcome of second-line docetaxel-based therapy, particularly for patients with ADC [95,123–126].”
Global trends in idiopathic pulmonary fibrosis mortality rates during 2001–2022
Harada, K., Nishimura, Y., Vu, Q. T., Yamamoto, M., Koyama, T., & Hagiya, H. (2025) · ERJ Open Research · doi:10.1183/23120541.00362-2025 · Cited by 9
Novel treatment strategies for lymphangioleiomyomatosis: a narrative review
Elia, D., Harari, S. A., Fan, L., Diesler, R., & Henske, E. P. (2025) · European Respiratory Review · doi:10.1183/16000617.0019-2025 · Cited by 8
Belmans, F., Persson, I. M., Bayat, S., Eaden, J. A., Vos, W. G., Jacob, J., Chambers, R. C., & Velde, G. V. (2025) · European Respiratory Review · doi:10.1183/16000617.0012-2025 · Cited by 7
Mohanan, M. P., Keles, G., Kulkarni, N. V., et al. (2025) · Microchemical Journal · doi:10.1016/j.microc.2025.115701 · Cited by 5
Matson, S. M., Ngo, L. T., Sugawara, Y., Fernando, V., Lugo, C., Kaczorowski-Worthley, A., Azeem, I., Harrison, A., Alsup, A., Schueddig, E., et al. (2025) · iScience · doi:10.1016/j.isci.2025.114125 · Cited by 19
Ryerson, C. J., Piciucchi, S., Travis, W. D., Nicholson, A. G., & Adegunsoye, A. (2026) · European Respiratory Journal · doi:10.1183/13993003.02312-2025 · Cited by 11
Self-citationClinical Impact of Surgical Lung Biopsy for Interstitial Lung Disease in a Reference Center
Guen, P. L., Iquille, J., Debray, M., Guyard, A., Roussel, A., Borie, R., Dombret, M.-C., Dupin, C., Ghanem, M., Taillé, C., et al. (2021) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2021.07.038 · Cited by 6
Prognostic value of the qSOFA in patients with acute exacerbation of idiopathic pulmonary fibrosis
Yamazaki, R., Nishiyama, O., Yoshikawa, K., Tohda, Y., & Matsumoto, H. (2023) · Respiratory Investigation · doi:10.1016/j.resinv.2023.02.006 · Cited by 5
Singer, D., Chastek, B. J., Sargent, A., Johnson, J., Shetty, S. S., Conoscenti, C., & Bernstein, E. J. (2023) · BMC Pulmonary Medicine · doi:10.1186/s12890-023-02637-8 · Cited by 6
Metadata
- Authors
- Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., Kim, D. S., Kolb, M., Nicholson, A. G., Noble, P. W., Selman, M., Taniguchi, H., Brun, M., Le Maulf, F., Girard, M., Stowasser, S., Schlenker-Herceg, R., Disse, B., & Collard, H. R.
- Affiliations
- NIHR Southampton Respiratory Biomedical Research Unit (GB)
- University of Washington (US)
- Nippon Medical School (JP)
- Ruhrlandklinik (DE)
- Université de Lyon (FR)
- Michigan Medicine (US)
- Royal Brompton & Harefield NHS Foundation Trust (GB)
- NHO Kinki Chuo Chest Medical Center (JP)
- Asan Medical Center (KR)
- McMaster University (CA)
- Cedars-Sinai Medical Center (US)
- Instituto Nacional de Enfermedades Respiratorias (MX)
- Tosei General Hospital (JP)
- Boehringer Ingelheim (Germany) (DE)
- University of California, San Francisco (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-05-29
- Volume
- 370
- Issue
- 22
- Pages
- 2071-2082
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2138871107
- Cited by
- 4,654
- References
- 21
- Citations by year
- 2026: 338 · 2025: 372 · 2024: 479 · 2023: 412 · 2022: 429 · 2021: 501 · 2020: 423 · 2019: 350 · 2018: 345 · 2017: 328 · 2016: 293 · 2015: 292 · 2014: 74
- FWCI
- 263.74
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Use Siena air (University of Siena) (submittedVersion, cc-by-nc-nd)
- Cineca Institutional Research Information System (Tor Vergata University) (submittedVersion)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- Digital Access to Libraries (submittedVersion)
- ePrints Soton (University of Southampton) (submittedVersion)
- IRIS UNIMORE (University of Modena and Reggio Emilia) (submittedVersion, cc-by)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- Funders
- Amgen
- Pfizer
- GlaxoSmithKline
- Sanofi
- Gilead Sciences
- Biogen
- Celgene
- FibroGen
- Ikaria
- University Hospital Southampton NHS Foundation Trust
- Massachusetts Medical Society
- Royal Brompton and Harefield NHS Foundation Trust
- Galecto
- Veracyte
- National Institute for Health and Care Research (NF-SI-0512-10157)
- Imperial College London
- Shionogi
- Genentech
- Japan Society for the Promotion of Science (24591149)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Keywords
- nintedanib, idiopathic pulmonary fibrosis, tyrosine kinase inhibitors, forced vital capacity decline, acute exacerbation, St George's Respiratory Questionnaire, drug safety, INPULSIS trials, lung function preservation, adverse events, diarrhea, liver enzymes, proteinuria, thrombocytopenia, neutropenia, antifibrotic therapy
- MeSH terms
- Aged, Double-Blind Method, Enzyme Inhibitors, Female, Humans, Indoles, Male, Middle Aged, Protein-Tyrosine Kinases, Quality of Life, Vital Capacity, Treatment Outcome, Disease Progression, Protein Kinase Inhibitors, Idiopathic Pulmonary Fibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.